The prognostic value of EEG in comatose patients after cardiac arrest (CA) has been an important clinical issue for decades. Research started in the 1960s with the classic study by Hockaday et al. 1 in which EEG predicted outcome with a not-so-great reliability of about 80%. At present, the management of post-CA patients often involves the induction of therapeutic hypothermia (TH). TH, a neuroprotective strategy, improves clinical outcomes in comatose patients after witnessed out-of-hospital CA from ventricular fibrillation in randomized controlled trials, 2 and it is standard of care for these patients. How to prognosticate outcome in post-CA patients treated with hypothermia has become a very active area of research, in particular regarding the value of EEG monitoring. In this issue of Neurology ® , Rossetti et al.
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Rossetti et al. evaluated the prognostic value of EEG findings during TH. They used elevated serum levels of neuron-specific enolase (NSE) as a surrogate marker of irreversible brain damage. They hypothesized that "malignant" EEG patterns were indicative of neuronal damage or death and sought support for this idea by correlating EEG with high NSE levels. The results of their study confirm previous observations, including ours, that some patients can have good clinical outcome after TH despite high serum NSE levels. 4 The main finding of this study, therefore, is not the pathophysiologic implication of the good but imperfect correlation of continuous EEG with serum NSE, but rather the poor prognosis associated with an unreactive background (with or without epileptiform discharges) or burst-suppression (the "malignant patterns") even during TH.
The interest in early EEG monitoring for patients with CA treated with hypothermia has been fueled by previous reports of exceptional cases in which treatment of postanoxic status epilepticus-even if associated with clinical myoclonus-was followed by favorable functional recovery. 5 This observation represented a conceptual shift; postanoxic status epilepticus-and particularly myoclonic status-had been traditionally considered a marker of uniformly poor outcome. Continuous EEG monitoring has become a part of TH protocols in many centers without solid justification or hard supporting evidence. We are only now learning how to use the information it provides.
What are the vital questions we should ask ourselves now?
The first question is whether treatment of electrographic seizures during TH can result in a good recovery. Based on our own experience and the cumulative evidence in the literature, it is becoming increasingly clear that aggressive treatment of electrographic seizures-with or without myoclonus-detected during TH does not change the poor outcome of these patients. 3, 4, 6, 7 Patients with seizures on continuous EEG during TH typically also have unreactive background and often a discontinuous pattern, as shown by Rossetti et al. Even if seizures can be abated by anticonvulsive therapy, the background remains unreactive and the patients remain comatose. In fact, this makes a lot of sense: seizures that occur during TH are actually occurring despite TH. TH can actually be used to stop status epilepticus 8 and only the most refractory seizures will occur while patients are hypothermic. When trying to abort these seizures we have had to resort to the prolonged use of anesthetic agents, with the resultant confounding effects on subsequent examinations that eventually cause a considerable delay in the assessment of prognosis.
But then what about those reports of patients recovering despite having seizures on EEG? Careful review of these cases, when sufficient information was provided, reveals that those seizures occurred during or after rewarming. 5, 6 We have noted that brief, self-limited myoclonus during rewarming is actually not rare. Seizures on EEG-with or without myoclonus-are less common, but treatment in such cases should be attempted, especially if status epilepticus develops from a continuous background.
The second question is whether prolonged continuous EEG monitoring is justified as a prognostic test. Continuous EEG is expensive and laborintensive. Unless the information it offers can be used to improve patients' outcomes, the additional cost and labor does not appear to be justifiable. We need studies to compare the value of prolonged continuous EEG vs routine 30-minute EEG recording at specific times (perhaps upon rewarming and 72 hours after CA in patients who remain comatose).
The third and most important question is what is the optimal model to assess the prognosis of patients with CA treated with hypothermia? We fully agree with Rossetti et al. that such model must integrate the information from multiple sources. Physical examination, EEG, somatosensory evoked potentials, serum NSE, and brain imaging should all be considered when assessing prognosis. Although in our experience the time to awakening after TH does not differ significantly from that observed in patients not treated with hypothermia, 9 it is always prudent to allow sufficient time before rendering a prognosis and it is crucial to consider and exclude the confounding effects of sedation and metabolic derangements. Residual effects of the pharmacologic sedation used during TH may affect the motor responses 5,10 and we must remain vigilant to the possibility that other prognostic indicators may become less reliable when TH is used, as appears to be the case with serum NSE levels.
The responsibility of neurologists evaluating patients with CA is to optimize the chances of recovery and accurately identify those patients who will not regain consciousness. We are clinicians and a careful physical examination should remain our principal tool. Additional tests-such as EEG-may serve a valuable role, but should not be used in isolation. The stakes are too high for any single test to determine the fate of these patients. 
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